Literature DB >> 21133886

Management of relapsed and refractory classical Hodgkin lymphoma in children and adolescents.

Stephen Daw1, Rob Wynn, Hamish Wallace.   

Abstract

There are a number of options for salvage treatment in children and adolescents with relapsed and refractory classical Hodgkin Lymphoma. These include salvage with standard dose chemotherapy, high dose chemotherapy with autologous stem cell transplant, allogeneic stem cell transplant or other novel approach. Radiotherapy has an important role in the salvage of some patients as part of a combined modality approach. This review outlines these salvage approaches and discusses whether the evidence from paediatric studies justifies a risk-adapted approach to salvage for individual patients or whether all patients should receive consolidation with high dose chemotherapy and autologous stem cell transplantation, which is often described as standard salvage management in adults. The important prognostic factors and how these may be used to allocate patients to standard versus high dose chemotherapy regimens are discussed. The role of allogeneic transplantation, novel agents and late effects will also be discussed.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 21133886     DOI: 10.1111/j.1365-2141.2010.08455.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

Review 1.  Management of Hodgkins Lymphoma: ICMR Consensus Document.

Authors:  Venkatraman Radhakrishnan; Gauri Kapoor; Brijesh Arora; Deepak Bansal; Tushar Vora; Maya Prasad; Girish Chinnaswamy; Siddharth Laskar; Sandeep Agarwala; Tanvir Kaur; G K Rath; Sameer Bakhshi
Journal:  Indian J Pediatr       Date:  2017-03-30       Impact factor: 1.967

2.  Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma.

Authors:  P Satwani; Z Jin; P L Martin; M Bhatia; J H Garvin; D George; S Chaudhury; J Talano; E Morris; L Harrison; J Sosna; M Peterson; O Militano; S Foley; J Kurtzberg; M S Cairo
Journal:  Leukemia       Date:  2014-06-18       Impact factor: 11.528

3.  Donor lymphocyte infusion is an effective therapy for relapsed Hodgkin lymphoma after reduced-intensity allogeneic hematopoietic stem cell transplantation.

Authors:  Utako Oba; Yuhki Koga; Aiko Suminoe; Toshiro Hara
Journal:  Int J Hematol       Date:  2014-08-06       Impact factor: 2.490

Review 4.  Antibody therapies for lymphoma in children.

Authors:  Verena de Zwart; Samantha C Gouw; Friederike A G Meyer-Wentrup
Journal:  Cochrane Database Syst Rev       Date:  2016-01-19

Review 5.  Bone Marrow Gene Therapy for HIV/AIDS.

Authors:  Elena Herrera-Carrillo; Ben Berkhout
Journal:  Viruses       Date:  2015-07-17       Impact factor: 5.048

6.  Defining the Inflammatory Plasma Proteome in Pediatric Hodgkin Lymphoma.

Authors:  Jennifer E Agrusa; Brooks P Scull; Harshal A Abhyankar; Howard Lin; Nmazuo W Ozuah; Rikhia Chakraborty; Olive S Eckstein; Nitya Gulati; Elmoataz Abdel Fattah; Nader K El-Mallawany; Rayne H Rouce; ZoAnn E Dreyer; Julienne Brackett; Judith F Margolin; Joseph Lubega; Terzah M Horton; Catherine M Bollard; M Monica Gramatges; Kala Y Kamdar; Kenneth L McClain; Tsz-Kwong Man; Carl E Allen
Journal:  Cancers (Basel)       Date:  2020-12-02       Impact factor: 6.639

7.  Beyond PET/CT in Hodgkin lymphoma: a comprehensive review of the role of imaging at initial presentation, during follow-up and for assessment of treatment-related complications.

Authors:  Abhishek R Keraliya; Sree Harsha Tirumani; Atul B Shinagare; Nikhil H Ramaiya
Journal:  Insights Imaging       Date:  2015-04-28

Review 8.  Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin.

Authors:  Xueyan Chen; Lorinda A Soma; Jonathan R Fromm
Journal:  Onco Targets Ther       Date:  2013-12-19       Impact factor: 4.147

9.  A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma.

Authors:  P Satwani; K W Ahn; J Carreras; H Abdel-Azim; M S Cairo; A Cashen; A I Chen; J B Cohen; L J Costa; C Dandoy; T S Fenske; C O Freytes; S Ganguly; R P Gale; N Ghosh; M S Hertzberg; R J Hayashi; R T Kamble; A S Kanate; A Keating; M A Kharfan-Dabaja; H M Lazarus; D I Marks; T Nishihori; R F Olsson; T D Prestidge; J M Rolon; B N Savani; J M Vose; W A Wood; D J Inwards; V Bachanova; S M Smith; D G Maloney; A Sureda; M Hamadani
Journal:  Bone Marrow Transplant       Date:  2015-08-03       Impact factor: 5.483

10.  Outcomes of Refractory and Relapsed Hodgkin Lymphoma With Autologous Stem-Cell Transplantation: A Single Institution Experience.

Authors:  Rabia Wali; Haleema Saeed; Naveed Patrus; Shehla Javed; Saadiya Javed Khan
Journal:  J Glob Oncol       Date:  2019-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.